Bayer: Hot Flashes trials
The registry lists 18 Hot Flashes studies with Bayer as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 8Phase 2 3Phase 3 7Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerActive, not recruitingNCT05587296Phase 3Results posted
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)CompletedNCT05099159Phase 3Results posted
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the MenopauseCompletedNCT05042362Phase 3Results posted
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the MenopauseCompletedNCT05030584Phase 3Results posted
- A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor SymptomsCompletedNCT03596762Phase 2Results posted
- Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor SymptomsCompletedNCT02865538Phase 1/2Results posted
- Endometrial Safety StudyCompletedNCT00522873Phase 3Results posted
- Low-dose Hormone Therapy for Relief of Vasomotor SymptomsCompletedNCT00446199Phase 3Results posted
- A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy WomenCompletedNCT06219902Phase 1
- A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy ParticipantsCompletedNCT05481528Phase 1
- A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female ParticipantsCompletedNCT05471817Phase 1
- A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 YearsCompletedNCT05381142Phase 1
- A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male ParticipantsCompletedNCT05351892Phase 1
- A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work NormallyCompletedNCT05071729Phase 1
- A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy AdultsCompletedNCT05061563Phase 1
- ZK283197 for Treatment of Vasomotor SymptomsCompletedNCT00537836Phase 2
- Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-FlushesCompletedNCT00206622Phase 4
- Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol PatchCompletedNCT00185237Phase 3